Sufrin G, Chasan S, Golio A, Murphy G P
Department of Urology, State University of New York, Buffalo 14203.
Semin Urol. 1989 Aug;7(3):158-71.
In renal carcinoma, the inappropriate, unscheduled, or aberrant production of hormones and other serologic markers and the resulting clinical or biochemical syndromes are unique manifestations of this tumor. The elaboration of biologically active factors by renal adenocarcinoma may add a metabolic burden to an already compromised host, and thus affect therapy and prognosis; they should be considered before ascribing symptoms to metastasis or dissemination. Similarly it has been suggested that the elaboration of biologically-inactive peptides and proteins is a very common concomitant of neoplasia and the identification of such factors may facilitate earlier diagnosis and novel therapies in patients with renal carcinoma.
在肾癌中，激素和其他血清学标志物的不适当、不定期或异常产生以及由此产生的临床或生化综合征是这种肿瘤的独特表现。肾腺癌产生生物活性因子可能会给本已受损的宿主增加代谢负担，从而影响治疗和预后；在将症状归因于转移或扩散之前应予以考虑。同样，有人提出，产生无生物活性的肽和蛋白质是肿瘤形成非常常见的伴随现象，识别这些因子可能有助于肾癌患者的早期诊断和新疗法的开发。
